guest ::
| Home > Publications database > Distinct relapse pattern across molecular ependymoma types. > print |
| 001 | 292426 | ||
| 005 | 20250113142142.0 | ||
| 024 | 7 | _ | |a 10.1093/neuonc/noae166 |2 doi |
| 024 | 7 | _ | |a pmid:39171767 |2 pmid |
| 024 | 7 | _ | |a 1522-8517 |2 ISSN |
| 024 | 7 | _ | |a 1523-5866 |2 ISSN |
| 024 | 7 | _ | |a altmetric:166579901 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-01709 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Obrecht-Sturm, Denise |0 0000-0002-3216-8452 |b 0 |
| 245 | _ | _ | |a Distinct relapse pattern across molecular ependymoma types. |
| 260 | _ | _ | |a Oxford |c 2025 |b Oxford Univ. Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1736774457_12089 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a Volume 27, Issue 1, January 2025, Pages 267–276 |
| 520 | _ | _ | |a Ependymoma (EPN) is not a uniform disease but represents different disease types with biological and clinical heterogeneity. However, the pattern of when and where different types of EPN relapse is not yet comprehensively described.We assembled 269 relapsed intracranial EPN from pediatric (n=233) and adult (n=36) patients from European and Northern American cohorts and correlated DNA methylation patterns and copy-number alterations with clinical information.The cohort comprised the following molecular EPN types: PF-EPN-A (n=177), ST-EPN-ZFTA (n=45), PF-EPN-B (n=31), PF-EPN-SE (n=12), and ST-EPN-YAP (n=4). First relapses of PF-EPN-B (PF: posterior-fossa) and PF-EPN-SE (SE: subependymoma) occurred later than of PF-EPN-A, ST-EPN-YAP (ST: supratentorial), or ST-EPN-ZFTA (median time to relapse: 4.3 and 6.0 years vs. 1.9/1.0/2.4 years; p<0.01). Metastatic or combined recurrences in PF-EPN-B and -A more often involved the spinal cord than in ST-EPN-ZFTA (72.7% and 40.0 vs. 12.5%; p<0.01). No distant relapses were observed in ST-EPN-YAP (n=4) or PF-EPN-SE (n=12). Post-relapse survival (PRS) was poor for PF-EPN-A and ST-EPN-ZFTA (5-year PRS: 44.5±4.4/47.8±9.1%), whereas PF-EPN-B and PF-EPN-SE displayed a 5-year PRS of 89.5±7.1/90.0±9.5% (p=0.03). However, 10-year PRS for PF-EPN-B dropped to 45.8±17.3%. Neither between radiation field and relapse pattern nor between radiation field and spinal involvement at relapse an impact was identified. Notably, all patients with relapsed ST-EPN-YAP did not receive upfront radiotherapy, but were successfully salvaged using irradiation at relapse.Relapse patterns of specific EPN types are different. Future clinical trials, treatment adaptions, duration of surveillance and diagnostics should be planned incorporating entity-specific relapse information. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a ependymoma |2 Other |
| 650 | _ | 7 | |a metastatic |2 Other |
| 650 | _ | 7 | |a recurrence |2 Other |
| 650 | _ | 7 | |a relapse |2 Other |
| 700 | 1 | _ | |a Schoof, Melanie |b 1 |
| 700 | 1 | _ | |a Eckhardt, Alicia |b 2 |
| 700 | 1 | _ | |a Mynarek, Martin |0 0000-0003-3302-2719 |b 3 |
| 700 | 1 | _ | |a Gilbert, Mark R |0 0000-0003-2556-9722 |b 4 |
| 700 | 1 | _ | |a Aldape, Kenneth |b 5 |
| 700 | 1 | _ | |a Armstrong, Terri S |b 6 |
| 700 | 1 | _ | |a Ramaswamy, Vijay |0 0000-0002-6557-895X |b 7 |
| 700 | 1 | _ | |a Bockmayr, Michael |b 8 |
| 700 | 1 | _ | |a von Hoff, Katja |b 9 |
| 700 | 1 | _ | |a Fleischhack, Gudrun |b 10 |
| 700 | 1 | _ | |a Adolph, Jonas E |b 11 |
| 700 | 1 | _ | |a Tippelt, Stephan |b 12 |
| 700 | 1 | _ | |a Pfister, Stefan |0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |b 13 |u dkfz |
| 700 | 1 | _ | |a Pajtler, Kristian |0 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d |b 14 |u dkfz |
| 700 | 1 | _ | |a Sturm, Dominik |0 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807 |b 15 |u dkfz |
| 700 | 1 | _ | |a Drexler, Richard |0 0000-0002-4830-3671 |b 16 |
| 700 | 1 | _ | |a Ricklefs, Franz L |b 17 |
| 700 | 1 | _ | |a Stepien, Natalia |b 18 |
| 700 | 1 | _ | |a Gojo, Johannes |b 19 |
| 700 | 1 | _ | |a Pietsch, Torsten |b 20 |
| 700 | 1 | _ | |a Warmuth-Metz, Monika |0 0000-0002-3544-319X |b 21 |
| 700 | 1 | _ | |a Kortmann, Rolf |b 22 |
| 700 | 1 | _ | |a Timmermann, Beate |b 23 |
| 700 | 1 | _ | |a Haberler, Christine |0 0000-0003-1016-0545 |b 24 |
| 700 | 1 | _ | |a Rutkowski, Stefan |b 25 |
| 700 | 1 | _ | |a Schüller, Ulrich |0 0000-0002-8731-1121 |b 26 |
| 773 | _ | _ | |a 10.1093/neuonc/noae166 |g p. noae166 |0 PERI:(DE-600)2094060-9 |n 1 |p 267–276 |t Neuro-Oncology |v 27 |y 2025 |x 1522-8517 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:292426 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-24 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEURO-ONCOLOGY : 2022 |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-24 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-24 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b NEURO-ONCOLOGY : 2022 |d 2023-10-24 |
| 920 | 1 | _ | |0 I:(DE-He78)B360-20160331 |k B360 |l Pädiatrische Gliomforschung |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B360-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|